Navigation Links
PriceSpective Continues Global Expansion With New San Diego Office

Dan Ross to Lead Business Development Team

PHILADELPHIA, Sept. 8 /PRNewswire/ -- PriceSpective, a value strategy consultancy that provides pricing and reimbursement services to pharmaceutical and biotechnology companies, is pleased to announce that it has hired Dan Ross to open its new San Diego office.

Ross brings 9 years of experience working with healthcare companies in both investment banking and strategic consulting capacities. His primary role will be to enhance PriceSpective's pricing and reimbursement, forecasting, and business development services. Within the business development offering, PriceSpective now has a team dedicated to assisting clients with licensing valuations, global pricing and market access due diligence, and negotiations associated with partnering products in early stage development.

This combination of enhanced early-stage business development services and PriceSpective's strategic pricing and reimbursement offerings enables the unique capability of providing clients with credible assumptions and model inputs that can drive long-range forecasts and serve as the foundation for licensing discussions. While located in one of the biotech rich areas of the United States, the San Diego office will also support PriceSpective's clients around the globe.

"As we execute our strategy to build our consulting and services capabilities," said CEO Steve Slovick, "Dan and other recent hires will ensure that our clients continue to receive high quality and high value advice. Our growing presence in the pharmaceutical consultancy continues to suggest that PriceSpective is rapidly moving toward the 'Best in Class' position we strive to achieve. This ongoing growth, such as the new San Diego office, will provide us with additional opportunities for expansion as we continue to plan for increased offerings and geographical coverage. I am delighted that someone as talented as Dan has joined our team."

Previously, Ross worked as the Director in charge of the global life sciences licensing, and valuation practice for Simon-Kucher& Partners (SKP). In this role, Ross worked closely with the bio-pharmaceutical and medical device companies to support a number of licensing transactions as an advisor to either the out- or in-licensing party. Prior to serving as a consultant to the health care industry, Ross worked with many of the same clients as an investment banker within Citigroup / Salomon Smith Barney's Health Care / Biotech Investment Banking division.

Ross received his Masters in Business Administration from Stanford University's Graduate School of Business.

About PriceSpective

PriceSpective is a management consulting firm specializing in innovative strategies to identify, capture and communicate value for companies in the biopharmaceutical arena. We are uniquely positioned to deliver expert guidance in integrated global pricing, reimbursement and market access strategy due to our depth of experience and the active engagement of our senior leadership.

Over the last year, PriceSpective has climbed from position #413 on Inc 500's list of 'Fastest Growing Private Companies in America' to # 174. PriceSpective has offices in Los Angeles, San Diego, Philadelphia and London and has a global staff of 49 professionals.

SOURCE PriceSpective
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Healthcare Continues to Use OnBase in Meaningful Ways
2. RainEarth (RNER) Continues to Expand its Marketing Force in China
3. Cord Blood America Continues International Expansion
4. Bio-Optronics Adds Innovative Electronic Data Capture (EDC) Solution to Clinical Conductor Clinical Trial Management System (CTMS), Continues to Improve Workflow and Productivity
5. Voler Systems Continues Investments and Expands Services
6. Waters Corporation Continues to Meet Todays Challenges for Improved Laboratory Operations with New Products at Pittcon 2009
7. SleepQuest Continues to Fight for Sleep Apnea Education
8. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
9. ACORN CRO Continues Growth in Strong Third Quarter
10. ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results
11. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
Post Your Comments:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):